PapersFlow Research Brief
Management of metastatic bone disease
Research Guide
What is Management of metastatic bone disease?
Management of metastatic bone disease encompasses the palliative strategies, including radiotherapy and surgical interventions, employed to treat bone metastases, particularly spinal tumors causing pain, fractures, and spinal cord compression.
The field includes 32,554 published works addressing spinal metastases, radiotherapy, surgical management, and prognostic factors. Key concerns involve vertebral compression fractures and metastatic epidural spinal cord compression. Stereotactic radiosurgery represents a focused approach for oligometastatic cases.
Topic Hierarchy
Research Sub-Topics
Stereotactic Radiosurgery for Spinal Metastases
This sub-topic studies precision radiotherapy delivery for metastatic epidural spinal cord compression, evaluating local control rates and pain relief. Researchers compare fractionation schemes and imaging guidance.
Surgical Decompression for Metastatic Spinal Cord Compression
Research assesses direct surgical resection versus laminectomy for relieving cord compression from bone metastases, focusing on neurological recovery and survival. Outcomes include randomized trial data on ambulation.
Prognostic Factors in Metastatic Spine Disease
Investigations identify clinical, radiographic, and molecular predictors of survival and skeletal events in spinal metastases. Scoring systems like SINS and Tokuhashi are refined for treatment decisions.
Radiotherapy Tolerance in Spinal Metastases
This area examines normal tissue dose limits for vertebral bodies, cord, and esophagus during palliative irradiation of bone metastases. Studies model re-irradiation risks and fractionation effects.
Management of Vertebral Compression Fractures in Metastases
Researchers evaluate vertebroplasty, kyphoplasty, and stabilization for pathological fractures from spinal tumors, assessing pain, stability, and cement leakage risks.
Why It Matters
Management of metastatic bone disease directly reduces skeletal morbidity, which affects the most common site of metastatic cancer and leads to pain requiring radiotherapy, hypercalcemia, pathologic fractures, and spinal cord compression (Coleman, 2006). Direct decompressive surgery improves outcomes over radiotherapy alone in spinal cord compression from metastatic cancer, as shown in a randomized trial (Patchell et al., 2005). Stereotactic ablative radiotherapy extended median overall survival to 41 months versus 28 months with standard palliative care in oligometastatic cancers, including bone sites (Palma et al., 2019). These interventions preserve function and quality of life in cancer patients with advanced bone involvement.
Reading Guide
Where to Start
"Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity" by Coleman (2006), as it provides foundational understanding of morbidity risks like pathologic fractures and spinal cord compression essential before exploring treatments.
Key Papers Explained
"Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity" (Coleman, 2006) outlines skeletal morbidity risks, which Patchell et al. (2005) address through direct decompressive surgery in "Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial," demonstrating superior outcomes over radiotherapy. Palma et al. (2019) extend this in "Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET)," showing survival benefits with precise radiation. Enneking et al. (1993) in "A System for the Functional Evaluation of Reconstructive Procedures After Surgical Treatment of Tumors of the Musculoskeletal System" provides the evaluation framework linking surgery to functional assessment.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current focus remains on refining stereotactic radiosurgery protocols for oligometastatic bone disease and integrating prognostic models for surgical selection, as no recent preprints or news indicate shifts beyond established trials like SABR-COMET.
Papers at a Glance
Frequently Asked Questions
What are the main clinical features of metastatic bone disease?
The skeleton is the most common site of metastatic cancer, producing morbidity through pain requiring radiotherapy, hypercalcemia, pathologic fracture, and spinal cord or nerve root compression. These events define skeletal-related events in patients with bone metastases (Coleman, 2006). Management targets these complications to alleviate symptoms.
How does direct surgical decompression compare to radiotherapy for metastatic spinal cord compression?
Direct decompressive surgical resection outperforms radiotherapy alone in treating spinal cord compression from metastatic cancer, based on a randomized trial. Surgery followed by radiotherapy improved ambulation and survival outcomes (Patchell et al., 2005). This approach addresses compression more effectively in eligible patients.
What role does stereotactic radiosurgery play in managing metastatic bone disease?
Stereotactic ablative radiotherapy serves as an alternative to standard palliative treatment for oligometastatic cancers, including bone metastases. In a phase 2 trial, it improved median survival from 28 to 41 months (Palma et al., 2019). It offers precise targeting for spinal and bone lesions.
What is the MSTS system in musculoskeletal tumor management?
The Musculoskeletal Tumor Society (MSTS) system provides a standardized functional evaluation for reconstructive procedures after surgical treatment of musculoskeletal tumors. It was developed for consistent reporting of limb salvage outcomes (Enneking et al., 1993). The system assesses pain, function, and emotional acceptance.
Why is pain management critical in metastatic bone disease?
Many outpatients with metastatic cancer experience considerable pain but receive inadequate analgesia despite guidelines. Effective treatment reduces suffering and improves quality of life (Cleeland et al., 1994). Pain often stems from bone metastases and requires targeted interventions.
Open Research Questions
- ? What prognostic factors best predict outcomes in surgical versus radiotherapeutic management of spinal metastases?
- ? How can stereotactic radiosurgery be optimized for metastatic epidural spinal cord compression?
- ? Which patients with vertebral compression fractures from bone metastases benefit most from prophylactic stabilization?
- ? What are the long-term functional outcomes of reconstructive surgery in metastatic bone disease using systems like MSTS?
Recent Trends
The field maintains steady output with 32,554 works, emphasizing spinal metastases management through radiotherapy and surgery, as in foundational papers like Coleman and Patchell et al. (2005).
2006No growth rate data or recent preprints signal changes, sustaining focus on palliative strategies for skeletal morbidity.
Research Management of metastatic bone disease with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Management of metastatic bone disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers